ArticleAngiogenesis2021
Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.
Article in Angiogenesis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis.Thrombosis research · 2022Pooled it
- Prognostic value of von Willebrand factor and ADAMTS-13 in patients with sepsis-induced coagulopathy.Research and practice in thrombosis and haemostasis · 2026Article
- Inflammatory and Endothelial Dysfunction Biomarkers Predict Severe COVID-19 in Hospitalized Patients: Development of the CCBR Model.Biomedicines · 2026Article
- Endothelial Biomarkers and Cytokine Profiles: Signatures of Mortality in Severe COVID-19.International journal of molecular sciences · 2026Observational
- Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study.International journal of molecular sciences · 2025Observational
- SARS-CoV-2 ORF7a activates the endothelium to release von Willebrand factor that promotes thrombosis.Research and practice in thrombosis and haemostasis · 2025Article
- Molecular Research on Coronavirus: Pathogenic Mechanisms, Antiviral Drugs, and New Vaccines.International journal of molecular sciences · 2024Article
- VEGF-A plasma levels are associated with impaired DLCO and radiological sequelae in long COVID patients.Angiogenesis · 2024Article
- Combined coagulation and inflammation markers as predictors of venous thrombo-embolism and death in COVID-19.Frontiers in medicine · 2024Article
- The modes of angiogenesis: an updated perspective.Angiogenesis · 2023Article
- SARS-CoV-2 infection and SLE: endothelial dysfunction, atherosclerosis, and thrombosis.Clinical rheumatology · 2023Review
- Pathological angiogenesis: mechanisms and therapeutic strategies.Angiogenesis · 2023Review
- A Clinical Qualification Protocol Highlights Overlapping Genomic Influences and Neuro-Autonomic Mechanisms in Ehlers-Danlos and Long COVID-19 Syndromes.Current issues in molecular biology · 2023Article
- Increased Binding of von Willebrand Factor to Sub-Endothelial Collagen May Facilitate Thrombotic Events ComplicatingToxins · 2023Article
- Inflammation and vascular remodeling in COVID-19 hearts.Angiogenesis · 2023Article
- Von Willebrand factor and the thrombophilia of severe COVID-19:Research and practice in thrombosis and haemostasis · 2023Article
- Microvascular Thrombosis as a Critical Factor in Severe COVID-19.International journal of molecular sciences · 2023Article
- Acute Kidney Injury and Blood Purification Techniques in Severe COVID-19 Patients.Journal of clinical medicine · 2022Review
- Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction.Journal of thrombosis and haemostasis : JTH · 2022Article
- Reduced ADAMTS13 Activity in Correlation with Pathophysiology, Severity, and Outcome of COVID-19: A Retrospective Observational Study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicrothrombosis is a hallmark of COVID-19. We previously described von willebrand factor (VWF) and their high molecular weight multimers (HMWMs) as potential trigger of microthrombosis.
objectivesInvestigate VWF activity with collagen-binding assay and ADAMTS13 in COVID-19. METHODS AND
resultsOur study enrolled 77 hospitalized COVID-19 patients including 37 suffering from a non-critical form and 40 with critical form. Plasma levels of VWF collagen-binding ability (VWF:CB) and ADAMTS13 activity (ADAMTS13:Act) were measured in the first 48 hours following admission. VWF:CB was increased in critical (631% IQR [460-704]) patients compared to non-critical patients (259% [235-330], p < 0.005). VWF:CB was significantly associated (r = 0.564, p < 0.001) with HMWMs. Moreover, median ADAMTS13:Act was lower in critical (64.8 IU/dL IQR 50.0-77.7) than non-critical patients (85.0 IU/dL IQR 75.8-94.7, p < 0.001), even if no patients displayed majors deficits. VWF:Ag-to-ADAMTS13:Act ratio was highly associated with VWF:CB (r = 0.916, p < 0.001). Moreover, VWF:CB level was highly predictive of COVID-19 in-hospital mortality as shown by the ROC curve analysis (AUC = 0.92, p < 0.0001) in which we identified a VWF:CB cut-off of 446% as providing the best predictor sensitivity-specificity balance. We confirmed this cut-off thanks to a Kaplan-Meier estimator analysis (log-rank p < 0.001) and a Cox-proportional Hazard model (HR = 49.1, 95% CI 1.81-1328.2, p = 0.021) adjusted on, BMI, C-reactive protein, and D-dimer levels.
conclusionVWF:CB levels could summarize both VWF increased levels and hyper-reactivity subsequent to ADAMTS13 overflow and, therefore, be a valuable and easy to perform clinical biomarker of microthrombosis and COVID-19 severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.